anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made to fit the femoral and tibial exposed metaphyses as a solid block with associated antibiotic cement coated tibial and femoral intramedullary rod, such that knee motion will be minimized.
This study aimed to assess the therapeutic effects of implementing the BioFire® Blood Culture Identification 2 (BCID2) Panel (bioMérieux, Marcy l'Etoile, France) in the clinical practice of children with sepsis. This retrospective cross-sectional study included children from 15 days of age to 18 years old with sepsis and of whom the BCID2 Panel was studied from the positive blood culture. If the antimicrobial treatment was changed according to the results of BCID2 Panel, it was recorded and re-grouped as targeted antimicrobial therapy, de-escalation of the antimicrobial treatment and shifting to another antimicrobial drug if any antimicrobial resistance was detected. Seven-days and thirty-days mortality rate was recorded. Thirty-two patients with 36 septic episodes with positive BCID2 Panel results were included. The median age was 10 months 15 days (ranging from 15 days to 16.5 years). The mean difference between having positive results by the BCID2 Panel and conventional culture methods was 82.2 ± 45.4 h (ranging from 12.3 to 207 h). Effect of the BCID2 Panel on the antimicrobial treatment was detected in 69.4% of the episodes (n = 25). Glycopeptides were ceased at 6 patients, piperacillin/tazobactam was ceased at 6 patients, and cefotaxime was ceased at one patient and de-escalation was achieved in 13 episodes which formed the 36.1% of the initial antimicrobial treatment.   Conclusion: The BCID2 Panel had an important impact on the patients care and optimization according to the principles of antimicrobial stewardship. The BCID2 Panel may be one of the key items for rapid and accurate diagnosis in children with sepsis. Blood culture is still the mainstay for especially detection of antimicrobial drug resistance, while BCID2 tests had several advantages such as speed and diagnostic accuracy as good as blood culture. What is Known: • The BioFire® Blood Culture Identification 2 (BCID2) Panel (bioMérieux, Marcy l'Etoile, France) is a well-validated assay that allows for the simultaneous identification of 43 nucleic acid targets associated with bloodstream infections within about 1 h. What is New: • BCID2 Panel had a direct impact on the patient's treatment decision at the 69.4% of the sepsis episodes. • The clinicians received the microbiological results 82.2 h earlier with BCID2 panel compared to blood culture methods with antimicrobial resistance and de-escalation of the antimicrobial drugs was achieved at 13 episodes which formed the 36.1% of the initial treatment.
The invention relates to medicine, in particular, to a medicinal agent for preventing (decelerating) the progression of the apoptotic changes in the cells of various organs and the transformation thereof into necrotic tissue damage. The inventive agent comprises at least one type of 3-oxypyridine or the derivative of 3-oxypyridine, at least one type of purine or the derivative of purine or a nicotine-amide-adenine-dinucleotide. The preferred 3-oxypyridin derivative is embodied in the form of 3-oxy-6-methyl-2-ethyl pyridine succinate. The preferred purine derivative is embodied in the form of inosine. The said medicinal agent can also contain an L-carnitine, alphoscerate choline, and be administered in the form of an injection, a pill, capsule, or suppository. The inventive medicinal agent exhibits a wide therapeutic range and low toxicity, which makes it possible to remove or minimize the causes of apoptotic change activation, to reduce the degree of necrotic tissue damage generated by the pathological process of different etiologies and to decelerate the organism aging process.
The present invention belongs to a medical care beverage. The medical care beverage is prepared by a way that plant sections comprising pine, cedar, mulberry, bamboo, liquorice, etc. and spirit which is brewed by grain are infused. The medical care beverage mainly treats rheumatoid diseases, has a certain therapeutic effect on osteoperiostitis, osteomyelitis, bone tuberculosis and apoplexy hemiplegia and has a health care function by frequent drinking. Wujie wine is a basic prescription, and relevant pharmaceutical can be additionally added according to the body condition of a patient so that second Wujie serial wine can be prepared. The Wujie wine has the advantages of scientific formula, convenient infusing and use, easy acquirement of raw materials, low cost, no damage of original nutrient components, rich selenium element, no pollution, no poison, no side effect and obvious therapeutic effect.
A card-type storage device includes a processing chip and a memory module. The processing chip is selectively operated in a data accessing mode or a data uploading mode. The memory module is electrically connected with the processing chip. A first data set generated by the medical device at a first time point and a second data set generated by the medical device at a second time point are stored in the memory module. In the data accessing mode, a first storage list is established by the processing chip according to the first data set, and the first storage list is updated as a second storage list according to the second data set. If the processing chip judges that the second data set satisfies a predetermined condition, the processing chip enters the data uploading mode.
Double-Blind subjects randomized to only placebo medication for 6 weeks in the short-term 041021 or 041022 asenapine trials, were randomized (double-blind) Into the long-term 041512 asenapine extension trial and received asenapine 5 mg BID for Week 1. After Week 1, subjects received asenapine (either 5 mg BID or 10 mg BID) for the remainder of the 52 week trial.
The utility model relates to a streamlined medical health preserving pillow, comprising cracked Chinese herbal medicine bags bundled by a piece of cotton cloth from up to bottom, the Chinese herbal medicines at the neck pillow position comprise safflower, buck grass, dahurian angelica roots, atractylis ovata and ephedra sinica stapf, and the Chinese herbal medicines at the head pillow position comprise chrysanthemum, eupatorium, cinnamon twig, gastrodia elata, flos magnoliae liliflorae and reed roots. Buckwheat husks are arranged under the Chinese herbal medicine bags which are used as a pillow inner, a layer of polyurethane foam is arranged under the pillow inner, and a pillow cover covers outside the pillow inner. The neck pillow position in the front of the pillow inner is high, the head pillow position at the rear of the pillow inner is low, the lateral faces of the pillow inner are of streamlined structures, and an arc concave surface is arranged in the center of the neck pillow position in the front of the long sides of the pillow inner in order to adapt to shoulder curve, thereby ensuring that people are more comfortable to lie on the lateral sides. The shape and the height of the streamlined medical health preserving pillow conform to rolling characteristics of cervical vertebra. The streamlined medical health preserving pillow can tract necks, has modest hardness, and provides people with high sleeping quality. The medicines enable arterial blood at necks and around the whole body to flow smoothly in order to provide sufficient blood to heads, and the streamlined medical health preserving pillow has the advantages of good air permeability, usability in four seasons, low price, good quality and environment protective property.
Fertility problems affect (1 in 10) couples in Western society, making it one of the most common serious health issues. Despite this, little is known about the causes of infertility, and thus patient counseling and treatment are suboptimal. With infertility being such a common problem, identification of any cause would impact on a large number of patients, allowing better counseling, clearer diagnoses and the possibility of making more informed choices (e.g. adoption vs. IVF treatment). The present invention provides methods to identify a cause of infertility in a subject based on the genotype of the subject, in particular, by evaluating the status of the gene encoding FK506 binding protein-like (FKBPL). In particular, the present invention relates to use of the status of the gene encoding FK506 binding protein-like for identification of a cause of an infertile phenotype in a subject. Also provided, are methods method for identifying an infertile phenotype in a subject, and identifying a cause of an infertile phenotype in a subject. This diagnostic tool finds wide clinical utility in the identification of a cause of infertility, resultantly impacting on a large number of patients. Further aspects of the present invention relate to the targeting of FKBPL in order to temporarily and reversibly induce infertility in a subject. Such aspects of the present invention find utility in the development of a male contraceptive pill. Moreover, due to the high degree of homology between the human and mouse FKBPL gene, FKBPL can be targeted in order to induce infertility in mice (or other species) as a form of pest control or animal husbandry.
A fracture liaison service model of care is widely recommended but data on its effectiveness regarding reduced risk of recurrent fracture and fracture related mortality are scarce. The investigators therefore aim to assess the risk of subsequent fractures and mortality after a clinical fracture in patients who present to hospitals with a standardized intervention program. Seven Norwegian hospitals will be Stepped Wedge Cluster Randomized to a standardized intervention program with startup date between May 2015 and Jan 2016. The intervention will last throughout 2018 with follow-up throughout 2019. Outcomes before and after the intervention will be compared and each hospital will act as its own control. The effect of the intervention will be measured by using national patient registries on fractures and mortality.
A method for rendering water-insoluble materials water-soluble is provided. The method is useful for solubilizing substantially water-insoluble bioactive materials such as drugs. This is accomplished by forming a non-covalently bonded complex between the drug and a polymer which is soluble in both water and an organic solvent. This is carried out by combining the desired medicinal agent with the polymer is an organic solvent, removing the solvent and dissolving the complex in water or aqueous buffer. When the organic solvent is evaporated, a solid complex is recovered which is water-soluble. Methods of treatment with the complexes are also provided.
Coronavirus disease 2019 (COVID‑19), a systemic illness caused by severe acute respiratory distress syndrome 2 (SARS‑CoV‑2), has triggered a worldwide pandemic with symptoms ranging from asymptomatic to chronic, affecting practically every organ. Melatonin, an ancient antioxidant found in all living organisms, has been suggested as a safe and effective therapeutic option for the treatment of SARS‑CoV‑2 infection due to its good safety characteristics and broad‑spectrum antiviral medication properties. Melatonin is essential in various metabolic pathways and governs physiological processes, such as the sleep‑wake cycle and circadian rhythms. It exhibits oncostatic, anti‑inflammatory, antioxidant and anti‑aging properties, exhibiting promise for use in the treatment of numerous disorders, including COVID‑19. The preventive and therapeutic effects of melatonin have been widely explored in a number of conditions and have been well‑established in experimental ischemia/reperfusion investigations, particularly in coronary heart disease and stroke. Clinical research evaluating the use of melatonin in COVID‑19 has shown various improved outcomes, including reduced hospitalization durations; however, the trials are small. Melatonin can alleviate mitochondrial dysfunction in COVID‑19, improve immune cell function and provide antioxidant properties. However, its therapeutic potential remains underexplored due to funding limitations and thus further investigations are required.
Schools receive refillable drinking bottles for all school children and drying racks for each classroom. Schools receive special project educational material and informational material and one training session for teachers. The intervention will be implemented during one school year (2018/2019), but schools can use the material and bottles also after ending of the intervention period.
Subjects in Cohort 2 will receive ANB-004 at a dose 2. The dose for Cohort 2 will be determined at the IDMC meeting. Depending on the DLT, the cohort may include 1 to 6 subjects in the first stage and 9 to 12 in the second stage.
PURPOSE:The titled inhibitor obtained by treating casein derived from bovine with trypsin. CONSTITUTION:An inhibitor against an enzume capable of converting angiotensin, comprising a compound shown by the formula as an active ingredient. The inhibitor is obtained by hydrolyzing casein derived from bovine with trypsin at 5.5-9.0pH, treating the hydrolyzate with hydrochloric acid to precipitate both trypsin and unhydrolyzed casin, removing them with a filter paper, neutralizing the prepared filtrate with an alkali such as NaOH, etc., and purifying it. It is especially effective as a hypotensor. Administration is generally carried out by intravenous injection, for example, 0.01-1mg/kg(animal) of it is applied by intravenous injection of an aqueous solution of the inhibitor. The inhibitor is applicable to mammals having the enzyme in an organism.
Participants first received Sound Production Treatment - Random (SPT-R) for 20 treatment sessions spanning approximately 7 weeks. After a washout period of 2 weeks, they then received Sound Production Treatment - Blocked (SPT-B) for 20 treatment sessions. Follow-up measures were conducted at 2, 6, and 10 weeks following the end of all treatment.
Thymoma is often associated with paraneoplastic neurologic diseases. Neural autoantibody testing is an important tool aiding diagnosis of thymoma and its autoimmune neurologic complications. Autoantibodies specific for muscle striational antigens and ion channels of the ligand-gated nicotinic acetylcholine receptor superfamily are the most prevalent biomarkers. The autoimmune neurologic disorders associating most commonly with thymoma are myasthenia gravis (MG), peripheral nerve hyperexcitability (neuromyotonia and Morvan syndrome), dysautonomia, and encephalitis. Patients presenting with these neurologic disorders should be screened for thymoma at diagnosis. Although they can cause profound disability, they usually respond to immunotherapy and treatment of the thymoma. Worsening of the neurologic disorder following surgical removal of a thymoma may herald tumor recurrence. Prompt recognition of paraneoplastic neurologic disorders is critical for patient management. A multidisciplinary approach is required for optimal management of neurologic autoimmunity associated with thymoma.
One of the 3 treatment arms in Aim 1: Placebo. No subjects were randomized to this arm.
The article presents a clinical observation demonstrating the functional results of orthotopic bladder plastic surgery according to Studer after radical cystectomy, which demonstrates the progression of chronic kidney disease (CKD) 2.5 years after surgery. According to the literature, patients who survived the early postoperative period with muscle-invasive bladder cancer and no lymph node involvement have a high probability of relapse-free and cancer-specific life expectancy of more than 15 years, but the probability of developing severe renal failure reaches 20%, which reduces the quality and duration of life of such patients. Progression of CKD in patients after orthotopic bladder plastic surgery according to Studer is possible against the background of high intravesical pressure in the emptying phase. According to clinical guidelines, intermittent autocatheterization is indicated for patients with neurogenic bladder dysfunction such as detrusor hypotension and high intravesical pressure during the voiding phase, minimizing the risk of upper urinary tract damage. Standards for managing patients with an orthotopic bladder do not provide such recommendations. Additional studies are needed to determine the advisability of persistent catheterization of an artificial bladder in the absence of residual urine but high intravesical pressure during urination.
The purpose of Schroth exercises is to rotate, lengthen and stabilize the spine in a three-dimensional plane. It is aimed to increase the patient's body awareness, to rotate the spine by inflating the deflated parts of the lungs with breathing, and to correct muscle posture asymmetries.

With different stimuli from the environment, some changes occur in the reorganization ability and strength of neurons and the synapses that neurons make with each other. This phenomenon, which is necessary for the adaptation of the organism to the environment, is called neuroplasticity. Thanks to neuroplasticity, some differences in brain structures are observed. Thanks to Schroth exercises, there is an intense proprioception sensory input to the body. At the same time, muscle strengthening occurs with controlled loading. Schroth exercises produce some effects on the brain with these features. In the study, the possible effects of Schroth exercises on the brain will be investigated.
Patients in the experimental group will be included in the face-to-face Phase I rehabilitation program until discharge and in the Phase II telerehabilitation program and sleep hygiene training for 3 weeks after discharge. Respiratory exercises will be performed as part of the phase I rehabilitation program until the patients are discharged. In addition, active range of motion and mobility exercises in bed, sitting position and standing, increasing distance walking and stair ascent and descent training will be provided. During the sessions, the patient's vital signs and clinical status will be monitored with a finger pulse oximeter and a blood pressure measuring device according to the patient's perceived degree of difficulty (Borg Scale). As part of the Phase II telerehabilitation program, respiratory exercises, calisthenic exercises and gait training will be performed.
PROBLEM TO BE SOLVED: To provide bioactive ingredients that include isolated bioactive fractions derived from cell juice of fresh biomass of a feverfew (Tanacetum parthenium) plant.SOLUTION: The present invention relates to processes for isolating bioactive fractions that are derived from cell juice of fresh biomass of a feverfew (Tanacetum parthenium) plant and that are either free of or substantially free of α-unsaturated γ-lactones (e.g., parthenolide). This processes involve providing fresh biomass of a feverfew (Tanacetum parthenium) plant. Suitable fresh biomass can include any part of the feverfew plant, including, for example, its leaves, flowers, shoots, stems, and roots. The fresh biomass is processed under conditions effective to yield a cell juice supernatant and a membrane fraction. The cell juice supernatant is treated under conditions effective to yield a first cell juice serum supernatant and a cytoplasm fraction precipitate. The cytoplasm fraction precipitate is then isolated as a bioactive fraction that is substantially free of α-unsaturated γ-lactones, particularly substantially free of parthenolide. The bioactive fraction has anti-inflammatory and antioxidant activity.
PURPOSE: To stimulate the immune system of an animal by administering somatotropin or prolactin into the animal to increase the production of macrophages and stimulate the oxidative metabolisms of the macrophages. CONSTITUTION: This method for stimulating the immune system of an animal comprises administering into the animal an immune system-stimulating amount of a protein selected from somatotropin which is a substance stimulating the growth of the skeleton, the retention of nitrogen and the synthesis of proteins and having a synthetic metabolism activity, and prolactin which is a substance having the activities of mammary gland stimulation/lactagogue. The protein is administered at a daily dose of 0.1-24mg/animal preferably by a parenteral administration method (e.g. intravenous or intramuscular injection, or subcutaneous transplant). The protein in such an amount as sufficiently giving the protein at a daily dose of 1-10mg/animal is preferably added to a buffer solution containing 0.025M of NaHCO3 and 0.025M of NaCO3 for an injectable receipt. Diseases capable of being treated with the protein include the trophic rhinitis and pleuropneumonia of pigs and the infectious respiratory system diseases and mastitis of cattle.
PURPOSE: Cerebral ischemia-reperfusion (CIR) injury is a devastating consequence of stroke characterized by oxidative stress-induced neuronal damage. Electroacupuncture (EA) has emerged as a potential therapeutic intervention for ischemic stroke, but its underlying mechanisms remain incompletely understood. This study aimed to elucidate whether EA exerts anti-oxidative stress effects against CIR injury by modulating the GSK-3β/Nrf2 pathway.
METHODS: CIR mouse models were established using the suture-occluded method and underwent EA pretreatment. Cognitive and neurologic function, cerebral infarct volume, and neuronal damage were assessed in mice. Oxidative stress levels and the expression of components of the GSK-3β/Nrf2 pathway in the cerebral cortex were measured. The regulatory effect of GSK-3β on Nrf2 and its role in electroacupuncture to alleviate oxygen-glucose deprivation/reoxygenation (OGD/R)-induced neuronal injury were investigated by modulating GSK-3β expression in HT22 hippocampal neuronal cells and electroacupuncture serum intervention. Ultimately, Nrf2 knockout mice, GSK-3β knockout mice, and wild-type mice treated with TBHQ (an Nrf2 activator) were utilized for further validation.
RESULTS: EA pretreatment improved cognitive impairment and neuronal damage induced by CIR injury. Mechanistically, EA inhibited oxidative stress in the cerebral cortex, manifested by reduced levels of reactive oxygen species and malondialdehyde, along with increased superoxide dismutase activity. Furthermore, EA upregulated the expression of Nrf2 and its downstream antioxidant enzymes HO-1 and NQO1, while Keap1 expression remained unaffected. In vitro, GSK-3β overexpression inhibited the protective effects of EA serum on OGD/R-induced neuronal damage. In vivo, knockout of either Nrf2 or Gsk-3β genes abolished the neuroprotective effects of EA, and TBHQ exerted effects similar to EA, confirming the significant role of GSK-3β/Nrf2 in mediating EA antioxidative effects.
CONCLUSION: EA exerts antioxidative stress effects against CIR injury by activating the GSK-3β/Nrf2 signaling pathway, independent of Keap1 regulation.